Gilead Strengthens its Early-Stage Pipeline by Acquiring Arresto Biosciences
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 1 (Table of Contents)
Published: 12 Jan-2011
DOI: 10.3833/pdr.v2011.i1.1419 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an effort to reduce its reliance on its market-leading HIV franchise, Gilead Sciences has entered into another diversifying, early-stage deal by purchasing Arresto Biosciences for US$225 M in cash and future sales-based payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS